HOME >> MEDICINE >> NEWS
Promising drug fails to improve COPD symptoms

NF-, and a number of studies have reported increased production of TNF in COPD patients. This increased production has been linked to weight loss, muscle weakness and muscle loss.

In addition, animal studies supported the prospect using the drug in COPD. When TNF- was infused into rats, they developed emphysema, which, along with chronic bronchitis, makes up most COPD cases. When the TNF- receptor was turned off in mice, they were less likely than mice that had not be genetically altered to develop emphysema when exposed to chronic cigarette smoke.

The latest study, however, did confirm a recently reported pilot study that found no improvement among the 14 COPD patients given infliximab.

In attempting to explain the disappointing results, the study authors speculate that, despite infliximab's efficacy in treating other inflammatory diseases, it may not be effective in COPD because other mediators, in addition to TNF-, are necessary to cause COPD. They also concede that six months may simply be too short a time period to see improvement.

However, an increased number of malignancies observed in infliximab-treated subjects, the authors said, raised concern about the safety of this drug in lung patients. Although the malignancies may have been present when the patients enrolled in the study, "the possibility that infliximab contributed to the progession, and thus the diagnosis, of malignancies remains a serious concern."

This safety issue, coupled with the "resoundingly negative results," make in unlikely that a longer trial will be undertaken, according to the accompanying editorial.


'"/>

Contact: Suzy Martin
smartin@thoracic.org
212-315-8631
American Thoracic Society
1-May-2007


Page: 1 2

Related medicine news :

1. Promising therapy for ALS delivers antisense drug directly to nervous system
2. Promising new treatment for ulcerative colitis sufferers
3. Promising advance in breast cancer research
4. Promising obesity therapy receives follow-on funding
5. Promising diagnostic tools for multiple sclerosis developed at Yale
6. Promising therapies for haemophilia & heart disease
7. Promising new TB drug enters clinical trial
8. Promising new West Nile therapy cures disease in mice
9. Government fails sleepy Judge Dodd
10. Pairing medical therapy with coronary intervention fails to reduce heart disease deaths
11. Community and clinic-based HIV-1 control program fails to decrease incidence of HIV-1 in Zimbabwe

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... Houston, TX (PRWEB) , ... February 24, 2017 ... ... now offering promotions on tooth replacement options at his office, Antoine Dental Center. ... dental implants for $18,499. Some restrictions may apply, but patients can learn more ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The ... recognition opportunities as well as advocacy for the state and region‘s technology businesses, ... 23. The Council's Innovation Forecast event highlights innovation throughout the region from ...
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... 2017 , ... Healthcare Associates of McKinney announced today that they ... 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in the ... As the practice has grown, the need for more space has been paramount. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017 Mederi Therapeutics today announced the ... 2468 patients who received  Stretta Therapy  to treat ... Systematic Review and Meta-Analysis of Controlled and Prospective ... of Gastroesophageal Reflux Disease ", was published in ... , MD, head of the Esophageal and Swallowing ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... Raymond James and Associates, 38 th ... 2017 in Orlando, FL. Cowen ... ET on March 7, 2017 in Boston, MA. ... 16, 2017 in Miami, FL. ...
Breaking Medicine Technology:
Cached News: